Table 5.
The correlation between LINC00671 expression and clinical features in 229 patients with PCa
| All cases | LINC00671 | |||
|---|---|---|---|---|
|
| ||||
| High expression | Low expression | P value | ||
| Age (year) | 0.486 | |||
| > 60 | 108 | 61 (56.5%) | 47 (43.5%) | |
| ≤ 60 | 121 | 67 (55.4%) | 54 (44.6%) | |
| Differentiation | ||||
| Well | 69 | 36 (52.2%) | 33 (47.8%) | 0.470 |
| Moderate | 87 | 48 (55.2%) | 39 (44.8%) | |
| Poor | 73 | 38 (52.1%) | 35 (47.9%) | |
| pN status | 0.007 | |||
| N0 | 123 | 71 (57.7%) | 52 (42.3%) | |
| N1-N2 | 106 | 43 (40.6%) | 63 (59.4%) | |
| pM status | 0.141 | |||
| M0 | 156 | 84 (53.8%) | 72 (46.2%) | |
| M1 | 73 | 33 (45.2%) | 40 (54.8%) | |
| Clinical stage | 0.221 | |||
| I | 79 | 45 (57.0%) | 34 (43.0%) | |
| II | 58 | 34 (58.6%) | 24 (41.4%) | |
| III | 53 | 26 (49.1%) | 27 (50.9%) | |
| IV | 39 | 16 (41.0%) | 23 (59.0%) | |
pN: pathological node; pM: pathological metastasis.